1414570-72-1

Basic information

• Product Name: N'-acetyl-5-amino-4-methyl-1-phenyl-1H-pyrazole-3-carbohydrazide
• Synonyms: N'-acetyl-5-amino-4-methyl-1-phenyl-1H-pyrazole-3-carbohydrazide
• CAS NO: 1414570-72-1
• Molecular Weight: 273.294
• Mol File: 1414570-72-1.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: N'-acetyl-5-amino-4-methyl-1-phenyl-1H-pyrazole-3-carbohydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: N'-acetyl-5-amino-4-methyl-1-phenyl-1H-pyrazole-3-carbohydrazide(1414570-72-1)
• EPA Substance Registry System: N'-acetyl-5-amino-4-methyl-1-phenyl-1H-pyrazole-3-carbohydrazide(1414570-72-1)

Safety Data

• Hazardous Substances Data: 1414570-72-1(Hazardous Substances Data)

Upstream product

• 524729-53-1 ethyl 3-cyano-2-oxobutanoate 
• 1367870-32-3 5-amino-4-methyl-1-phenyl-1H-pyrazole-3-carboxylic acid 
• 1068-57-1 acetic acid hydrazide 
• 543-27-1 isobutyl chloroformate 
• 1015765-43-1 ethyl 5-amino-4-methyl-1-phenyl-1H-pyrazole-3-carboxylate 

Downstream Products

• 1414570-70-9 4-methyl-3-(5-methyl-1,3,4-oxadiazol-2-yl)-1-phenyl-1H-pyrazol-5-amine 

Relevant articles and documents

N-BICYCLIC ARYL,N'-PYRAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

N-(MONOCYCLIC ARYL),N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.